Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.


Clinical Trial Description

This study adopts a multicenter, prospective, and observational cohort study design and does not involve randomization, control, and blinding. Patients with type 2 diabetes mellitus who were prescribed Dorzagliatin according to the package insert and physician's judgment in routine medical practice setting will be included, and the data of these patients during 52-week Dorzagliatin treatment will be collected to evaluate the safety of long-term medication. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06263348
Study type Interventional
Source Hua Medicine Limited
Contact Yi Zhang, MD,PhD
Phone +8618502130980
Email yzhang@huamedicine.com
Status Recruiting
Phase Phase 4
Start date December 20, 2023
Completion date April 30, 2026